Literature DB >> 1347154

Presynaptic effects of dopexamine hydrochloride in the canine kidney.

A S Bass1.   

Abstract

The effects of dopexamine on the vasoconstrictor response to renal nerve stimulation and noradrenaline were determined in anesthetized dogs. Renal vasoconstriction was repeated during the sequential administration of iso-osmotic saline, dopexamine, dopexamine plus the DA1-dopamine receptor antagonist, SCH 23390, and dopexamine plus SCH 23390 and the DA2-dopamine receptor antagonist, domperidone. Renal nerve stimulation-induced vasoconstriction did not change with dopexamine or dopexamine plus SCH 23390, but increased with the addition of domperidone. Dopexamine also potentiated noradrenaline-induced vasoconstriction. Antagonists alone had no affect on the vasoconstrictor response to either stimulus. The findings suggest that the absence of an effect of dopexamine on neuronally-induced renal vasoconstriction was a consequence of a balance between its actions at presynaptic DA2-dopamine receptors (attenuated vasoconstriction) and its ability to inhibit the uptake1 transporter (enhanced vasoconstriction).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347154     DOI: 10.1007/bf00175466

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  8 in total

1.  Presynaptic dopamine receptors as mediators of dopamine-induced inhibition of neurogenic vasoconstriction.

Authors:  M F Lokhandwala; J P Buckley
Journal:  Eur J Pharmacol       Date:  1977-10-01       Impact factor: 4.432

Review 2.  Effects of drugs and physiological factors in the disposition of catecholamines in blood vessels.

Authors:  S Spector; J Tarver; B Berkowitz
Journal:  Pharmacol Rev       Date:  1972-06       Impact factor: 25.468

3.  Dopaminergic inhibition of cardiac sympathetic nerve function by pergolide.

Authors:  R J Barrett; M F Lokhandwala
Journal:  Eur J Pharmacol       Date:  1982-01-08       Impact factor: 4.432

4.  Potentiation by dopexamine of the cardiac responses to circulating and neuronally released norepinephrine: a possible mechanism for the therapeutic effects of the drug.

Authors:  A S Bass; M B Murphy; J D Kohli; L I Goldberg
Journal:  J Cardiovasc Pharmacol       Date:  1989-04       Impact factor: 3.105

5.  Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors.

Authors:  R A Brown; J Dixon; J B Farmer; J C Hall; R G Humphries; F Ince; S E O'Connor; W T Simpson; G W Smith
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

6.  Mechanisms mediating the positive inotropic and chronotropic changes induced by dopexamine in the anesthetized dog.

Authors:  A S Bass; J D Kohli; N Lubbers; L I Goldberg
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

7.  Inhibition of Uptake1 by dopexamine hydrochloride in vitro.

Authors:  P D Mitchell; G W Smith; E Wells; P A West
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

8.  Contrasting effects of dopexamine hydrochloride on electrolyte excretion in canine kidney.

Authors:  A S Bass
Journal:  J Pharmacol Exp Ther       Date:  1990-05       Impact factor: 4.030

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.